OLIVENOL™ livin' is produced in GMP-certified facilities in Australia with strict adherence to the Australian Therapeutic Goods Administration (TGA) manufacturing, safety and quality control guidelines. It has achieved GRAS (Generally Regarded As Safe) status as recognised by the FDA and is certified Halal. Although OLIVENOL™ livin' has met stringent safety assessments, our belief in a natural approach towards our products drives us to continuously research and work towards replacing all synthetic compounds with natural ingredients.

OLIVENOL™ livin' is backed by extensive medical studies. The patented Olea europaea (olive) extract has high bioavailability and offers remarkable free-radical protection because its minute molecular size allows it to be quickly absorbed, distributed and metabolised in the body.

And to ensure that you get the finest from nature, OLIVENOL™ livin' uses only 100% certified organic olives. The highest safety standards are applied to the patented extraction process named Integrale™ which is completely non-toxic and solvent-free. This way, the natural integrity of the biophenols is maintained and environmental pollution is prevented. With OLIVENOL™ livin', you are assured of all the healthy goodness of olives minus the fat or calories.

A patent is an exclusive right which, when granted, gives the inventor a monopoly to make, use or sell the invention within a jurisdiction (or jurisdictions) for a fixed period of time. Patent protection is crucial to facilitate enhanced market exclusivity and prevent market entry of low cost substitutes. However, in the dietary supplement field for instance, we can hardly find any products with patent protection at all. This is because of the lengthy time and cost required to obtain even one patent. Furthermore, only novel and useful inventions are qualified to seek for patent protection.

The approved patents are:

1) US 6,165,475, December 26, 2000.
2) US 6,197,308, March 6 2001
3) US 6,416,808, July 9, 2002.
4) US 6,936,287, August 30, 2005
5) US 7,261,909, August 28, 2007